Oluyemi Okupe Sells 9,868 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe sold 9,868 shares of the business’s stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $19.96, for a total transaction of $196,965.28. Following the completion of the sale, the chief financial officer now directly owns 195,988 shares of the company’s stock, valued at $3,911,920.48. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Oluyemi Okupe also recently made the following trade(s):

• On Friday, September 20th, Oluyemi Okupe sold 12,651 shares of Hims & Hers Health stock. The shares were sold at an average price of $16.79, for a total transaction of $212,410.29.
• On Tuesday, September 3rd, Oluyemi Okupe sold 11,609 shares of Hims & Hers Health stock. The shares were sold at an average price of $14.60, for a total transaction of $169,491.40.

Hims & Hers Health Stock Down 3.4 %

HIMS traded down $0.67 during trading on Tuesday, hitting $18.77. 19,402,621 shares of the company’s stock were exchanged, compared to its average volume of 7,941,402. The business’s 50 day moving average is $16.50 and its two-hundred day moving average is $17.31. Hims & Hers Health, Inc. has a fifty-two week low of $5.65 and a fifty-two week high of $25.74. The stock has a market cap of $4.03 billion, a P/E ratio of -1,877.00 and a beta of 1.06.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, August 5th. The company reported $0.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.04 by $0.02. Hims & Hers Health had a net margin of 1.70% and a return on equity of 5.25%. The business had revenue of $315.65 million during the quarter, compared to the consensus estimate of $302.43 million. During the same quarter last year, the company posted ($0.03) earnings per share. The firm’s quarterly revenue was up 51.8% compared to the same quarter last year. On average, sell-side analysts forecast that Hims & Hers Health, Inc. will post 0.22 earnings per share for the current year.

Institutional Trading of Hims & Hers Health

Large investors have recently added to or reduced their stakes in the stock. Nisa Investment Advisors LLC boosted its position in Hims & Hers Health by 679.2% during the second quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock worth $37,000 after purchasing an additional 1,603 shares during the period. Quest Partners LLC boosted its position in shares of Hims & Hers Health by 5,944.1% in the second quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock valued at $72,000 after acquiring an additional 3,507 shares during the period. Van ECK Associates Corp bought a new position in shares of Hims & Hers Health in the second quarter valued at approximately $111,000. Amalgamated Bank boosted its position in shares of Hims & Hers Health by 55.9% in the second quarter. Amalgamated Bank now owns 6,566 shares of the company’s stock valued at $133,000 after acquiring an additional 2,354 shares during the period. Finally, Daiwa Securities Group Inc. bought a new position in shares of Hims & Hers Health in the second quarter valued at approximately $142,000. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on HIMS shares. Truist Financial upped their price objective on shares of Hims & Hers Health from $13.00 to $23.00 and gave the stock a “hold” rating in a research report on Thursday, July 18th. Needham & Company LLC started coverage on shares of Hims & Hers Health in a report on Thursday, August 22nd. They set a “buy” rating and a $24.00 target price on the stock. Deutsche Bank Aktiengesellschaft boosted their target price on shares of Hims & Hers Health from $16.00 to $23.00 and gave the stock a “hold” rating in a report on Wednesday, August 7th. Bank of America reduced their target price on shares of Hims & Hers Health from $24.00 to $20.00 and set a “buy” rating on the stock in a report on Friday, September 13th. Finally, Imperial Capital lowered shares of Hims & Hers Health from an “outperform” rating to an “in-line” rating in a report on Friday, August 9th. Eight investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, Hims & Hers Health currently has a consensus rating of “Moderate Buy” and an average target price of $19.86.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.